Adoption of Pathologic Complete Response as a Surrogate End Point in Neoadjuvant Trials in HER2-Positive Breast Cancer Still an Open Question

Tomasz Burzykowski¹, Everardo D Saad², Marc Buyse³

Affiliations

¹ International Drug Development Institute, Louvain-la-Neuve, Belgium2Interuniversity Institute for Biostatistics and Statistical Bioinformatics, Hasselt University, Belgium.
² International Drug Development Institute, Louvain-la-Neuve, Belgium3Dendrix Research, Sao Paulo, Brazil.
³ Interuniversity Institute for Biostatistics and Statistical Bioinformatics, Hasselt University, Belgium4International Drug Development Institute, San Francisco, California.

PMID: 27892994
DOI: 10.1001/jamaoncol.2016.3941

Comment

Adoption of Pathologic Complete Response as a Surrogate End Point in Neoadjuvant Trials in HER2-Positive Breast Cancer Still an Open Question

Tomasz Burzykowski et al. JAMA Oncol. 2017.

. 2017 Mar 1;3(3):416.

doi: 10.1001/jamaoncol.2016.3941.

Authors

Tomasz Burzykowski¹, Everardo D Saad², Marc Buyse³

Affiliations

¹ International Drug Development Institute, Louvain-la-Neuve, Belgium2Interuniversity Institute for Biostatistics and Statistical Bioinformatics, Hasselt University, Belgium.
² International Drug Development Institute, Louvain-la-Neuve, Belgium3Dendrix Research, Sao Paulo, Brazil.
³ Interuniversity Institute for Biostatistics and Statistical Bioinformatics, Hasselt University, Belgium4International Drug Development Institute, San Francisco, California.

PMID: 27892994
DOI: 10.1001/jamaoncol.2016.3941

No abstract available

PubMed Disclaimer

Comment in

Adoption of Pathologic Complete Response as a Surrogate End Point in Neoadjuvant Trials in HER2-Positive Breast Cancer Still an Open Question-Reply.
Berry DA. Berry DA. JAMA Oncol. 2017 Mar 1;3(3):416-417. doi: 10.1001/jamaoncol.2016.3947. JAMA Oncol. 2017. PMID: 27892985 No abstract available.

Comment on

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.
Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P, Swain SM, Prowell T, Loibl S, Wickerham DL, Bogaerts J, Baselga J, Perou C, Blumenthal G, Blohmer J, Mamounas EP, Bergh J, Semiglazov V, Justice R, Eidtmann H, Paik S, Piccart M, Sridhara R, Fasching PA, Slaets L, Tang S, Gerber B, Geyer CE Jr, Pazdur R, Ditsch N, Rastogi P, Eiermann W, von Minckwitz G. Cortazar P, et al. Lancet. 2014 Jul 12;384(9938):164-72. doi: 10.1016/S0140-6736(13)62422-8. Epub 2014 Feb 14. Lancet. 2014. PMID: 24529560 Review.
Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes: A Meta-Analysis.
Broglio KR, Quintana M, Foster M, Olinger M, McGlothlin A, Berry SM, Boileau JF, Brezden-Masley C, Chia S, Dent S, Gelmon K, Paterson A, Rayson D, Berry DA. Broglio KR, et al. JAMA Oncol. 2016 Jun 1;2(6):751-60. doi: 10.1001/jamaoncol.2015.6113. JAMA Oncol. 2016. PMID: 26914222

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Adoption of Pathologic Complete Response as a Surrogate End Point in Neoadjuvant Trials in HER2-Positive Breast Cancer Still an Open Question

Affiliations

Adoption of Pathologic Complete Response as a Surrogate End Point in Neoadjuvant Trials in HER2-Positive Breast Cancer Still an Open Question

Authors

Affiliations

Comment in

Comment on

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Research Materials

Miscellaneous